Vorinostat: all 244 studies that test it

Page 3 of 3. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00816283Phase 1
• Vorinostat in Combination With Vinorelbine in Patients With Advanced CancerTerminatedNCT00801151Phase 1
• Vorinostat in Treating Women With Ductal Carcinoma in Situ of the BreastCompletedNCT00788112Phase 1
• Vorinostat and Low Dose Cytarabine for High Risk MyelodysplasiaCompletedNCT00776503Phase 1/2
• A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian CancerStatus unknownNCT00772798Phase 2
• A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent GlioblastomaCompletedNCT00762255Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)CompletedNCT00750178Phase 1
• Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00744354Phase 1
• Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung CancerCompletedNCT00731952Phase 1
• Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT00729118Phase 1
• HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast CancerCompletedNCT00719875Phase 1
• Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung CancerTerminatedNCT00702572Phase 1
• Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLCTerminatedNCT00697476Phase 1/2
• Phase I Study of Vorinostat and Sorafenib in Advanced CancerCompletedNCT00635791Phase 1
• Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.TerminatedNCT00565227Phase 1
• Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal CancerCompletedNCT00537121Phase 1
• Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver DysfunctionCompletedNCT00499811Phase 1
• Vorinostat and Palliative RadiotherapyCompletedNCT00455351Phase 1
• Clinical Trial of SAHA in Patients With Breast CancerStatus unknownNCT00416130Phase 1/2
• Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaActive, not recruitingNCT00392353Phase 1/2
• Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other DiseasesCompletedNCT00357708Phase 1
• Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00357305Phase 1
• Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal CancerCompletedNCT00336141Phase 1
• Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell LymphomaActive, not recruitingNCT00336063Phase 1
• Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid TumorsCompletedNCT00331955Phase 1
• Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic SyndromesCompletedNCT00331513Phase 1
• Vorinostat and Alvocidib in Treating Patients With Advanced Solid TumorsCompletedNCT00324480Phase 1
• Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00310024Phase 1
• Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid TumorsCompletedNCT00287937Phase 1
• Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory AnemiaCompletedNCT00278330Phase 1
• Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00275080Phase 1
• Vorinostat and Temozolomide in Treating Patients With Malignant GliomasActive, not recruitingNCT00268385Phase 1
• Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00243100Phase 1
• Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00227513Phase 1
• Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid TumorsCompletedNCT00138177Phase 1
• Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity CancerCompletedNCT00132067Phase 2
• A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)CompletedNCT00127140Phase 1
• A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)TerminatedNCT00126451Phase 2
• Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00121277Phase 1
• A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)TerminatedNCT00109109Phase 1
• An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)CompletedNCT00097929Phase 2
• Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)CompletedNCT00091559Phase 2
• Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced CancerCompletedNCT00045006Phase 1
• Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous TherapyCompletedNCT00005634Phase 1

← Vorinostat overview